Axsome Therapeutics Entered into an Exclusive License Agreement with Pharmanovia to Develop and Commercialize Sunosi (solriamfetol) in Europe
Shots:
- Axsome will receive $66M up front and is eligible to receive ~$101M in sales-based and other milestones along with royalty on net sales
- Pharmanovia will be responsible for marketing Sunosi, a dual-acting dopamine and norepinephrine reuptake inhibitor in EU and MENA regions, and will lead all local clinical and regulatory activities and requirements incl. studies in a pediatric patient
- Sunosi is designed to improve wakefulness in adults with excessive daytime sleepiness due to narcolepsy or OSA in the EU and certain countries in the MENA. The therapy was approved in the EU in 2020, based on PBO-controlled studies for EDS associated with narcolepsy or OSA which showed the superiority of Sunosi over PBO
Ref: GlobeNewswire | Image: Axsome Therapeutics
Related Post:- axsome Therapeutics Reports P-III (ACCORD) Trial Results of AXS-05 for the Treatment of Alzheimer’s Disease Agitation
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
